• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune Checkpoint Inhibitor-Related Myocarditis, Myopathy, and More: Unraveling the Tangled Science of Immune-Related Adverse Events.

作者信息

Al-Mondhiry Jafar, Barac Ana

机构信息

Inova Schar Cancer Institute, Fairfax, Virginia, USA; University of Virginia School of Medicine, Charlottesville, Virginia, USA.

Inova Schar Cancer Institute, Fairfax, Virginia, USA; Inova Schar Heart and Vascular, Fairfax, Virginia, USA; Georgetown University School of Medicine, Washington, DC, USA. Electronic address: https://twitter.com/AnaBaracCardio.

出版信息

JACC CardioOncol. 2025 Apr;7(3):265-267. doi: 10.1016/j.jaccao.2025.03.004.

DOI:10.1016/j.jaccao.2025.03.004
PMID:40246384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12046833/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c7b/12046833/63130395f349/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c7b/12046833/63130395f349/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c7b/12046833/63130395f349/ga1.jpg

相似文献

1
Immune Checkpoint Inhibitor-Related Myocarditis, Myopathy, and More: Unraveling the Tangled Science of Immune-Related Adverse Events.免疫检查点抑制剂相关的心肌炎、肌病及其他：解读免疫相关不良事件的复杂科学
JACC CardioOncol. 2025 Apr;7(3):265-267. doi: 10.1016/j.jaccao.2025.03.004.
2
[A case of myopathy, myocarditis, and encephalitis with nonconvulsive status epileptics after immune checkpoint inhibitor therapy for ureter cancer].[输尿管癌免疫检查点抑制剂治疗后出现肌病、心肌炎、脑炎并伴有非惊厥性癫痫持续状态1例]
Rinsho Shinkeigaku. 2022 May 31;62(5):395-398. doi: 10.5692/clinicalneurol.cn-001725. Epub 2022 Apr 26.
3
Immune checkpoint inhibitor-related myocarditis.免疫检查点抑制剂相关心肌炎
Jpn J Clin Oncol. 2018 Jan 1;48(1):7-12. doi: 10.1093/jjco/hyx154.
4
Immune checkpoint inhibitor myocarditis.免疫检查点抑制剂性心肌炎。
Curr Opin Cardiol. 2019 May;34(3):303-306. doi: 10.1097/HCO.0000000000000622.
5
Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy.免疫检查点抑制剂相关肌病：一种临床病理特征独特的肌病。
Brain Commun. 2020 Nov 2;2(2):fcaa181. doi: 10.1093/braincomms/fcaa181. eCollection 2020.
6
Fatal Case of Immune-Related Myocarditis and Myositis Due to Treatment with Immune Checkpoint and Tyrosine Kinase Inhibitors.免疫检查点抑制剂和酪氨酸激酶抑制剂治疗导致的免疫相关性心肌炎和肌炎致死病例
Acta Med Port. 2024 Dec 2;37(12):865-868. doi: 10.20344/amp.21306. Epub 2024 Oct 14.
7
Immune Checkpoint Inhibitor-Related Myocarditis With or Without Concomitant Myopathy: Clinical Findings and Cardiovascular Outcomes.伴或不伴合并性肌病的免疫检查点抑制剂相关心肌炎：临床发现与心血管结局
JACC CardioOncol. 2025 Apr;7(3):252-264. doi: 10.1016/j.jaccao.2025.02.005. Epub 2025 Mar 17.
8
Immune checkpoint inhibitor-associated myocarditis: from pathophysiology to rechallenge of therapy - a narrative review.免疫检查点抑制剂相关性心肌炎：从病理生理学到治疗再挑战 - 一篇叙述性综述。
Future Cardiol. 2023 Feb;19(2):91-103. doi: 10.2217/fca-2022-0120. Epub 2023 Apr 20.
9
[Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].免疫检查点抑制剂相关心肌炎的研究进展
Zhongguo Fei Ai Za Zhi. 2021 Sep 20;24(9):668-672. doi: 10.3779/j.issn.1009-3419.2021.102.27. Epub 2021 Sep 15.
10
Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy.免疫检查点抑制剂相关性肌炎：一种独特形式的炎症性肌病。
J Clin Rheumatol. 2022 Oct 1;28(7):367-373. doi: 10.1097/RHU.0000000000001874. Epub 2022 Jun 14.

本文引用的文献

1
Immune Checkpoint Inhibitor-Related Myocarditis With or Without Concomitant Myopathy: Clinical Findings and Cardiovascular Outcomes.伴或不伴合并性肌病的免疫检查点抑制剂相关心肌炎：临床发现与心血管结局
JACC CardioOncol. 2025 Apr;7(3):252-264. doi: 10.1016/j.jaccao.2025.02.005. Epub 2025 Mar 17.
2
Cardiac Troponin I and T in ICI Myocarditis Screening, Diagnosis, and Prognosis.心肌肌钙蛋白I和T在免疫检查点抑制剂相关性心肌炎的筛查、诊断及预后中的应用
JACC CardioOncol. 2024 Aug 6;6(5):804-807. doi: 10.1016/j.jaccao.2024.07.001. eCollection 2024 Oct.
3
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
癌症免疫治疗学会（SITC）免疫检查点抑制剂相关免疫相关不良事件（irAEs）术语的共识定义。
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006398.
4
Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor-Induced Myocarditis.生物标志物趋势、免疫检查点抑制剂诱发心肌炎的发病率及转归
JACC CardioOncol. 2022 Dec 20;4(5):689-700. doi: 10.1016/j.jaccao.2022.11.004. eCollection 2022 Dec.
5
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.免疫相关不良事件、住院和治疗恢复与接受单药或联合免疫治疗的转移性黑色素瘤患者生存的关系。
JAMA Netw Open. 2022 Dec 1;5(12):e2245596. doi: 10.1001/jamanetworkopen.2022.45596.
6
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：ASCO 指南更新。
J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1.
7
Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.免疫检查点抑制剂相关性心肌炎合并肌炎/重症肌无力重叠综合征：病例系统综述。
Oncologist. 2021 Dec;26(12):1052-1061. doi: 10.1002/onco.13931. Epub 2021 Aug 25.
8
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.神经免疫相关免疫检查点抑制剂不良事件的共识疾病定义。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002890.
9
Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials.免疫治疗药物与化疗药物在实体瘤中的不良反应谱比较：一项随机临床试验的系统评价和荟萃分析。
Ann Oncol. 2020 Jan;31(1):50-60. doi: 10.1016/j.annonc.2019.10.008.
10
Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution.免疫检查点抑制剂相关肌炎：拓展免疫治疗革命心脏并发症的范围
Circulation. 2018 Aug 14;138(7):743-745. doi: 10.1161/CIRCULATIONAHA.118.035898.